Lean Hogs (LH)

Labcorp Hldgs에 대한 매도 수량은 투자자에게 Labcorp Hldgs의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Labcorp Hldgs (NYSE:LH) 주식, 공매도 수량 보고

Labcorp Holdings

Labcorp Hldgs

Laboratory Corp

Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.

DoorDash

News

Movers

ALNY

CHRW

COKE

CVNA

DASH

DXCM

EXAS

Laboratory Corporation Of America Holdings

PYPL

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 이그젝트 사이언스(NASDAQ:EXAS)가 예상보다 나은 2분기 재무 결과를 보고하고 트윈스트랜드 바이오사이언스(TwinStrand Biosciences)와 독점 라이센스 계약을 발표한 후 주가는 26.60% 상승했다. 몇몇 분석가들은 주식에 대한 가격 예측을 하향 조정했다.

도어대시와 이그젝트 사이언스는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (7월 28일-8월 3일)

Labcorp Holdings Inc

Leo Holdings Corp II Warrants (07/01/2028)

Lucira Health Inc Ordinary Shares

LIC HSG FIN S/GDR 144A by Lic Housing Finance Ltd.

LIGHTHOUSE GLOGAL HLDGS by Lighthouse Global Holdings Inc.

Lighthouse Global Holdings Inc

LEHMAN BRO HLDC/T 6.00% M by Lehman Brothers Holdings, Inc.

Lehman Brothers Holdings Capital Trust V

LEADER HILL CORP by Leader Hill Corp.

LIFEHOUSE RETIREMENT PPTY by LifeHouse Retirement Properties, Inc.

Lianhe Sowell International Group Ltd - Ordinary Shares

Lianhe Sowell International Group Ltd

LIGHTSTONE VALUE REIT by Lightstone Value Plus REIT Inc.

Lightstone Value Plus REIT I Inc

LIANHUA SUPERMKT HLDGS CO by Lianhua Supermarket Holdings Ltd.

Lianhua Supermarket Holdings Co Ltd

LIANHUA SPRMKT UNSP/ADR by Lianhua Supermarket Holdings Ltd.

L3Harris Technologies Inc

Lhyfe SA

In the latest quarter, 8 analysts provided ratings for Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $276.0, with a high estimate of $300.00 and a low estimate of $260.00. This current average has increased by 5.11% from the previous average price target of $262.57. 
<img src="https://www.benzinga.com/files/images/story/2025/1743631264_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Labcorp Hldgs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jamie Clark</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Buy</td>
<td>$276.00</td>
<td>-</td>
</tr>
<tr>
<td>Ralph Giacobbe</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$300.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$260.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$260.00</td>
<td>$271.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$290.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$271.00</td>
<td>$249.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$286.00</td>
<td>$293.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$265.00</td>
<td>$260.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Labcorp Hldgs. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Labcorp Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Labcorp Hldgs's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Labcorp Hldgs analyst ratings.</a>
<h2>Get to Know Labcorp Hldgs Better</h2>
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Labcorp Hldgs's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, Labcorp Hldgs showcased positive performance, achieving a revenue growth rate of 9.76% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Labcorp Hldgs's net margin excels beyond industry benchmarks, reaching 4.31%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.77%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Labcorp Hldgs's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.78%, the company showcases efficient use of assets and strong financial health.
Debt Management: Labcorp Hldgs's debt-to-equity ratio is below the industry average. With a ratio of 0.9, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Assessing Labcorp Hldgs: Insights From 8 Financial Analysts

Redburn Atlantic analyst Jamie Clark initiates coverage on Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Buy rating and announces Price Target of $276.

Price Target

Initiation

Redburn Atlantic Initiates Coverage On Labcorp Hldgs with Buy Rating, Announces Price Target of $276

Labcorp Reveals Nationwide Launch Of pTau-217/Beta Amyloid 42 Ratio, New Blood-based Biomarker Test To Aid In Diagnosis Of Alzheimer's Disease

Health Care

General

Labcorp Will Acquire Select Assets Of Bioreference Health, A Wholly Owned Subsidiary Of Opko Health For $225M, Including $192.5M Payable At Closing And Up To $32.5M In An Earnout Based On Performance

10 analysts have shared their evaluations of Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $274.8, a high estimate of $300.00, and a low estimate of $260.00. Witnessing a positive shift, the current average has risen by 4.8% from the previous average price target of $262.22.
<img src="https://www.benzinga.com/files/images/story/2025/1741089659_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Labcorp Hldgs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ralph Giacobbe</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$300.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$260.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$260.00</td>
<td>$271.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$290.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$271.00</td>
<td>$249.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$286.00</td>
<td>$293.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$265.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$270.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$271.00</td>
<td>$262.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$275.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Labcorp Hldgs. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Labcorp Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Labcorp Hldgs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Labcorp Hldgs's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Labcorp Hldgs analyst ratings.</a>
<h2>About Labcorp Hldgs</h2>
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Financial Insights: Labcorp Hldgs</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Labcorp Hldgs's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 9.76%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Labcorp Hldgs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.31% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.77%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Labcorp Hldgs's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.78% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.9, Labcorp Hldgs adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 10 Analyst Ratings Have To Say About Labcorp Hldgs

Citigroup analyst Ralph Giacobbe upgrades Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) from Neutral to Buy and raises the price target from $250 to $300.

Upgrades

Citigroup Upgrades Labcorp Hldgs to Buy, Raises Price Target to $300

Labcorp Hldgs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) short percent of float has fallen 3.63% since its last report. The company recently reported that it has 1.83 million shares sold short, which is 2.92% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.69 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Labcorp Hldgs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740758442_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Labcorp Hldgs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Labcorp Hldgs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Labcorp Hldgs's peer group average for short interest as a percentage of float is 9.75%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Is the Market Bullish or Bearish on Labcorp Hldgs?

Labcorp Announced Today The Clinical Availability Of Labcorp Plasma Completetm, A Circulating Tumor Dna (Ctdna)-based Comprehensive Genomic Profiling Solution For Patients With Advanced Solid Tumors

Labcorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>), a global leader of innovative and comprehensive laboratory services, announced today the clinical availability of <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4368475-1&amp;h=1155357821&amp;u=https%3A%2F%2Foncology.labcorp.com%2Fplasma-complete&amp;a=Labcorp%C2%AE+Plasma+CompleteTM">Labcorp&#xAE; Plasma CompleteTM</a>, a circulating tumor DNA (ctDNA)-based comprehensive genomic profiling solution for patients with advanced solid tumors. The liquid biopsy test enables oncologists to perform comprehensive genomic profiling to inform personalized treatment decisions – all from a simple blood draw.

Labcorp Launches Liquid Biopsy Test to Help Personalize Cancer Treatment

Piper Sandler analyst David Westenberg maintains Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Neutral and raises the price target from $240 to $260.

Piper Sandler Maintains Neutral on Labcorp Holdings, Raises Price Target to $260

Barclays analyst Jack Meehan maintains Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Equal-Weight and lowers the price target from $271 to $260.

Barclays Maintains Equal-Weight on Labcorp Holdings, Lowers Price Target to $260

Jefferies analyst Tycho Peterson maintains Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Buy and raises the price target from $275 to $290.

Jefferies Maintains Buy on Labcorp Holdings, Raises Price Target to $290

Thursday,&nbsp;Laboratory Corp&nbsp;(NYSE: LH) reported fourth-quarter 2024 adjusted earnings per share of $3.45, up from $3.30 a year ago, beating&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $3.39</a>.
Sales increased 9.8% year-over-year to $3.33 billion, almost in line with the consensus of $3.31 billion.
The increase was due to organic revenue growth of 5.4%, acquisitions, net of divestitures of 4%, and foreign&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43523377/labcorp-announces-2024-fourth-quarter-and-full-year-results" rel="noreferrer noopener">currency translation of 0.3%</a>.
&#8220;In 2024, Labcorp delivered exceptional results driven by both organic and inorganic growth,&#8221; said&nbsp;Adam Schechter, chairman and CEO of Labcorp&#8230;Additionally, we strengthened our presence in key high growth areas including oncology, women&#8217;s health, neurology and autoimmune disease. In 2025, we are positioned to deliver strong growth and margin expansion across both Diagnostics Laboratories and Biopharma Laboratory Services&#8230;&#8221;
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
Adjusted operating income for the quarter was&nbsp;$423.2&nbsp;million, or 12.7% of revenue, compared to&nbsp;$394.9 million, or 13%, in the fourth quarter.
William Blair analyst Andrew F. Brackmann writes, &#8220;We continue to believe the underlying business at Labcorp is on solid footing, as the diagnostics segment benefits from favorable macro tailwinds and the BLS segment sees solid growth in central labs (albeit decelerating off tough comps) and early development returns to growth.&#8221;
This positions the stock well for 2025, with stable guidance and potential for gains if the company&#8217;s momentum continues.
William Blair reiterates the Outperform rating.
Guidance: LabCorp expects 2025 adjusted EPS of 15.60-$16.40 versus the consensus of $16.0. It expects 2025 sales of $13.9 billion-$14.1 billion versus consensus Of $13.8 billion.
The guidance includes 2025 Diagnostics Laboratories sales growth of 6.5%- 7.7% and Biopharma Laboratory Services&nbsp;sales growth of 3.0%- 5.0%.
Price Action:&nbsp;Laboratory stock is down 0.92% at $247.68 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43523277/volkswagen-unveils-plan-for-e20000-entry-level-electric-car" target="_blank" rel="noreferrer noopener">Volkswagen Unveils Plan For Entry-Level, $20K ID Electric Car: Details</a></li>
</ul>
Photo by Gorodenkoff via Shutterstock

Analyst Color

Earnings

Guidance

Labcorp Q4 Earnings: Revenue And EPS Beat, Expects Strong 2025 Growth, Analyst Reiterates Outperform On Stable 2025 Outlook

Labcorp shares are trading lower. The company reported Q4 financial results.

Guidance for 2025
The following guidance assumes foreign exchange rates effective as of December&nbsp;31, 2024, for the full year. Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases and dividends.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="5" rowspan="1">(Dollars in billions, except per share data)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Results</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1">2025 Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2024</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Low</td>
<td colspan="1" rowspan="1">High</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Labcorp Enterprise (1)(2)</td>
<td colspan="1" rowspan="1">$13.01</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">6.7&nbsp;%</td>
<td colspan="1" rowspan="1">8.0&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Diagnostics Laboratories (3)</td>
<td colspan="1" rowspan="1">$10.14</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">6.5&nbsp;%</td>
<td colspan="1" rowspan="1">7.7&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Biopharma Laboratory Services (4)</td>
<td colspan="1" rowspan="1">$2.92</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">3.0&nbsp;%</td>
<td colspan="1" rowspan="1">5.0&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS</td>
<td colspan="1" rowspan="1">$14.57</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$15.60</td>
<td colspan="1" rowspan="1">$16.40</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow</td>
<td colspan="1" rowspan="1">$1.10</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$1.10</td>
<td colspan="1" rowspan="1">$1.25</td>
</tr>
</tbody>
</table>
</figure>

Labcorp Expects 2025 Sales Of $13.88B-$14.05B Versus Consensus Of $13.79B, and Adjusted EPS Of $15.60-$16.40 Versus Consensus Of $16.02

Laboratory Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) reported quarterly earnings of $3.45 per share which beat the analyst consensus estimate of $3.39 by 1.77 percent. This is a 4.55 percent increase over earnings of $3.30 per share from the same period last year. The company reported quarterly sales of $3.33 billion which beat the analyst consensus estimate of $3.31 billion by 0.63 percent. This is a 9.76 percent increase over sales of $3.03 billion the same period last year.

Laboratory Corp Q4 2024 Adj EPS $3.45 Beats $3.39 Estimate, Sales $3.33B Beat $3.31B Estimate

AAMI

AFRM

AGCO

AMRK

AMZN

APTV

BILL

CCEC

CIGI

CLFD

CLSK

CRNC

CTLP

DOCS

EMBC

ENTG

EXPE

EXPO

FARM

FBIN

FTNT

GOOS

GPRO

GTES

GTIM

HUBG

IBEX

IDCC

IIIV

ILMN

INTR

KVUE

LADR

LESL

LION

LITE

LIVE

LQDT

LSPD

LTRX

MAGN

MATW

MCFT

MCHP

MKTX

MPWR

MSGE

MTSI

Earnings Scheduled For February 6, 2025

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $273.0, with a high estimate of $286.00 and a low estimate of $265.00. This current average has increased by 3.1% from the previous average price target of $264.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1738620063_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Labcorp Holdings's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jack Meehan</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$271.00</td>
<td>$249.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$286.00</td>
<td>$293.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$265.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$270.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$271.00</td>
<td>$262.00</td>
</tr>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$275.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Labcorp Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Labcorp Holdings compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Labcorp Holdings's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Labcorp Holdings's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Labcorp Holdings analyst ratings.</a>
<h2>Get to Know Labcorp Holdings Better</h2>
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Labcorp Holdings: Financial Performance Dissected</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, Labcorp Holdings showcased positive performance, achieving a revenue growth rate of 7.37% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Labcorp Holdings's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 5.16%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Labcorp Holdings's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.09%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.96%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Labcorp Holdings's debt-to-equity ratio is below the industry average at 0.94, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 6 Analysts Discuss Labcorp Holdings Stock

Barclays analyst Jack Meehan maintains Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Equal-Weight and raises the price target from $249 to $271.

Barclays Maintains Equal-Weight on Labcorp Holdings, Raises Price Target to $271

UBS analyst Kevin Caliendo maintains Labcorp Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Buy and lowers the price target from $293 to $286.

UBS Maintains Buy on Labcorp Holdings, Lowers Price Target to $286

Press Releases

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests

Labcorp to Announce Fourth Quarter Financial Results on February 6, 2025

Dividends

LABCORP DECLARES QUARTERLY DIVIDEND

Labcorp to Speak at the 43rd Annual J.P. Morgan Healthcare Conference

Labcorp Announces 2024 Fourth Quarter and Full Year Results

Labcorp Announces Clinical Availability of Liquid Biopsy Test to Guide Personalized Treatment Plans for Patients with Advanced Solid Tumors

Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

Labcorp to Announce First Quarter Financial Results on April 29, 2025

Labcorp to Offer HPV and STI Self-Collection Options in Labcorp Patient Service Centers and Participating Physician Offices Nationwide

Labcorp Launches First-of-its-Kind Immunoassay to Accelerate Path to Diagnosis of Alzheimer's Disease

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

Labcorp Hldgs

매도 수량

Labcorp Hldgs (NYSE:LH) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌